Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind, Single and Multiple Dose Study to Determine Pharmacodynamic Markers, Pharmacokinetic Parameters, and Safety of ALTO-203 in Patients With Major Depressive Disorder

NCT06391593 is registered in ClinicalTrials.gov with Alto Neuroscience as lead sponsor.

NCT NCT06391593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06391593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind, Single and Multiple Dose Study to Determine Pharmacodynamic Markers, Pharmacokinetic Parameters, and Safety of ALTO-203 in Patients With Major Depressive Disorder
Lead sponsor
Alto Neuroscience
Phase
Phase 2
Overall status
Completed
Start date
March 25, 2024
Completion date
April 21, 2025
Enrollment
69 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

anhedonia, major depressive disorder